Exelixis, Inc.
https://www.exelixis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Exelixis, Inc.
Achieve Life Sciences Believes It Has The New Chantix
Armed with an old drug and new data, the group is aiming to revitalize the smoking cessation market.
Fast Start To Oral Phenylephrine Efficacy Complaints As US FDA Considers 'Any Action'
Two days after FDA advisory panel’s meeting to discuss whether oral phenylephrine is effective for nasal congestion, complaints filed in federal court in multiple states alleging manufacturers knowingly misled public about ingredient’s efficacy. FDA’s potential response to NDAC’S finding wouldn’t come as soon.
Exelixis Adds Insilico Deal In Search Of Growth Beyond Cabometyx
After feeling the heat from activist investor Farallon Capital Management earlier this year, CEO Michael Morrissey has defended its spending on in-house R&D and in-licensing as it announced a new oncology deal.
‘Small Biotech Exception’ From Medicare Price Negotiation Granted To Four Drugs For 2026
CMS has not disclosed how many requests for the exception it received but will follow up with applicants regarding its decisions this month.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- X-Ceptor Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice